Surgical outcomes and immunohistochemical features for gastrointestinal stomal tumors (GISTs) of the stomach

With special reference to prognostic factors

Sungsoo Park, Je Seock Ryu, Seung Yeop Oh, Wan-Bae Kim, Ju-Han Lee, Yang Seok Chae, Seung Joo Kim, Chong Suk Kim, Young Jae Mok

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background/Aims: Stomach is the most common site of gastrointestinal stromal tumors (GISTs). But the preoperative pathologic diagnosis is often difficult to make and it is hard to decide an appropriate surgical extent and also adjuvant therapy due to obscure malignant potential. Our purpose was to observe the outcomes for the patients with GIST of the stomach and reveal the significant prognostic factors. Methodology: Forty patients operated for primary GIST of the stomach expressing CD117 were studied. We evaluated immunohistochemical and clinicopathologic features, and analyzed them to reveal the significant prognostic factors. The surgical outcomes of the patients were also investigated. Results: Multivariate analysis for disease-free survival disclosed mitotic activity was the only independent factor, but the immunohistochemical features did not have any prognostic value. Among the patients with recurrence, all of the patients treated with imatinib mesylate (formerly STI-571) have survived until now, but half of the untreated patients died. Conclusions: In gastric GISTs, most important prognostic factor is mitotic count, not tumor size. We suggest that the wider application of imatinib mesylate to clinically malignant gastric GIST as adjuvant therapy may contribute to the improvement of outcomes.

Original languageEnglish
Pages (from-to)1454-1457
Number of pages4
JournalHepato-Gastroenterology
Volume54
Issue number77
Publication statusPublished - 2007 Jul 1

Fingerprint

Stomach
Neoplasms
Gastrointestinal Stromal Tumors
Disease-Free Survival
Multivariate Analysis
Recurrence
Therapeutics
Imatinib Mesylate

Keywords

  • Gastrointestinal stromal tumor
  • Prognosis
  • Stomach
  • Surgical outcome

ASJC Scopus subject areas

  • Medicine(all)
  • Hepatology
  • Gastroenterology

Cite this

Surgical outcomes and immunohistochemical features for gastrointestinal stomal tumors (GISTs) of the stomach : With special reference to prognostic factors. / Park, Sungsoo; Ryu, Je Seock; Oh, Seung Yeop; Kim, Wan-Bae; Lee, Ju-Han; Chae, Yang Seok; Kim, Seung Joo; Kim, Chong Suk; Mok, Young Jae.

In: Hepato-Gastroenterology, Vol. 54, No. 77, 01.07.2007, p. 1454-1457.

Research output: Contribution to journalArticle

@article{c6e276c9fb164831950b7f758911fad8,
title = "Surgical outcomes and immunohistochemical features for gastrointestinal stomal tumors (GISTs) of the stomach: With special reference to prognostic factors",
abstract = "Background/Aims: Stomach is the most common site of gastrointestinal stromal tumors (GISTs). But the preoperative pathologic diagnosis is often difficult to make and it is hard to decide an appropriate surgical extent and also adjuvant therapy due to obscure malignant potential. Our purpose was to observe the outcomes for the patients with GIST of the stomach and reveal the significant prognostic factors. Methodology: Forty patients operated for primary GIST of the stomach expressing CD117 were studied. We evaluated immunohistochemical and clinicopathologic features, and analyzed them to reveal the significant prognostic factors. The surgical outcomes of the patients were also investigated. Results: Multivariate analysis for disease-free survival disclosed mitotic activity was the only independent factor, but the immunohistochemical features did not have any prognostic value. Among the patients with recurrence, all of the patients treated with imatinib mesylate (formerly STI-571) have survived until now, but half of the untreated patients died. Conclusions: In gastric GISTs, most important prognostic factor is mitotic count, not tumor size. We suggest that the wider application of imatinib mesylate to clinically malignant gastric GIST as adjuvant therapy may contribute to the improvement of outcomes.",
keywords = "Gastrointestinal stromal tumor, Prognosis, Stomach, Surgical outcome",
author = "Sungsoo Park and Ryu, {Je Seock} and Oh, {Seung Yeop} and Wan-Bae Kim and Ju-Han Lee and Chae, {Yang Seok} and Kim, {Seung Joo} and Kim, {Chong Suk} and Mok, {Young Jae}",
year = "2007",
month = "7",
day = "1",
language = "English",
volume = "54",
pages = "1454--1457",
journal = "Hepato-Gastroenterology",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "77",

}

TY - JOUR

T1 - Surgical outcomes and immunohistochemical features for gastrointestinal stomal tumors (GISTs) of the stomach

T2 - With special reference to prognostic factors

AU - Park, Sungsoo

AU - Ryu, Je Seock

AU - Oh, Seung Yeop

AU - Kim, Wan-Bae

AU - Lee, Ju-Han

AU - Chae, Yang Seok

AU - Kim, Seung Joo

AU - Kim, Chong Suk

AU - Mok, Young Jae

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Background/Aims: Stomach is the most common site of gastrointestinal stromal tumors (GISTs). But the preoperative pathologic diagnosis is often difficult to make and it is hard to decide an appropriate surgical extent and also adjuvant therapy due to obscure malignant potential. Our purpose was to observe the outcomes for the patients with GIST of the stomach and reveal the significant prognostic factors. Methodology: Forty patients operated for primary GIST of the stomach expressing CD117 were studied. We evaluated immunohistochemical and clinicopathologic features, and analyzed them to reveal the significant prognostic factors. The surgical outcomes of the patients were also investigated. Results: Multivariate analysis for disease-free survival disclosed mitotic activity was the only independent factor, but the immunohistochemical features did not have any prognostic value. Among the patients with recurrence, all of the patients treated with imatinib mesylate (formerly STI-571) have survived until now, but half of the untreated patients died. Conclusions: In gastric GISTs, most important prognostic factor is mitotic count, not tumor size. We suggest that the wider application of imatinib mesylate to clinically malignant gastric GIST as adjuvant therapy may contribute to the improvement of outcomes.

AB - Background/Aims: Stomach is the most common site of gastrointestinal stromal tumors (GISTs). But the preoperative pathologic diagnosis is often difficult to make and it is hard to decide an appropriate surgical extent and also adjuvant therapy due to obscure malignant potential. Our purpose was to observe the outcomes for the patients with GIST of the stomach and reveal the significant prognostic factors. Methodology: Forty patients operated for primary GIST of the stomach expressing CD117 were studied. We evaluated immunohistochemical and clinicopathologic features, and analyzed them to reveal the significant prognostic factors. The surgical outcomes of the patients were also investigated. Results: Multivariate analysis for disease-free survival disclosed mitotic activity was the only independent factor, but the immunohistochemical features did not have any prognostic value. Among the patients with recurrence, all of the patients treated with imatinib mesylate (formerly STI-571) have survived until now, but half of the untreated patients died. Conclusions: In gastric GISTs, most important prognostic factor is mitotic count, not tumor size. We suggest that the wider application of imatinib mesylate to clinically malignant gastric GIST as adjuvant therapy may contribute to the improvement of outcomes.

KW - Gastrointestinal stromal tumor

KW - Prognosis

KW - Stomach

KW - Surgical outcome

UR - http://www.scopus.com/inward/record.url?scp=34547618234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547618234&partnerID=8YFLogxK

M3 - Article

VL - 54

SP - 1454

EP - 1457

JO - Hepato-Gastroenterology

JF - Hepato-Gastroenterology

SN - 0172-6390

IS - 77

ER -